 BOSTON, Sept. 30, 2021 GLOBE NEWSWIRE -- Monte Rosa Therapeutics, Inc. NASDAQ: GLUE, a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical data for the companys GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer has been selected for a late-breaking poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 7-10. 